Europe Immunotherapy Market Sizing and Forecast till 2036
報告摘要
The European Immunotherapy Market Sizing and Forecast till 2035 report provides a comprehensive assessment of market valuation, clinical adoption, and pipeline commercialization across European healthcare systems. Growth is driven by expanding clinical indications for immune checkpoint inhibitors, CAR-T cell therapies, monoclonal antibodies, and cancer vaccines.
However, high treatment costs, stringent European health technology assessment (HTA) reimbursement reviews, and risk of severe immune-related adverse events create market access friction. Biopharmaceutical companies are investing in predictive biomarker diagnostics and value-based pricing agreements to secure reimbursement approvals across European nations. This research assists oncology executives and biotech investors in commercial planning.
授權報價
| Single User Price | $750 USD |
| Multi User Licence (up to 10 users) | $1,000 USD |
| Enterprisewide Price (Global Site License) | $1,250 USD |
目錄 Table of Contents
TABLE OF CONTENT
1.1 Overview 11
1.2 Europe 13
1.2.1 GERMANY 19
1.2.2 UK 22
1.2.3 FRANCE 25
1.2.4 ITALY 28
1.2.5 SPAIN 31
1.2.6 BELGIUM 34
1.2.7 DENMARK 38
1.2.8 NETHERLAND 42
1.2.9 SWEDEN 46
1.2.10 POLAND 50
1.2.11 REST OF EUROPE 54
圖表清單 List of Tables & Figures
LIST OF TABLES
TABLE 1 NA & EUROPE IMMUNOTHERAPYS MARKET, BY REGION, 2019-2035 (USD MILLION) 12
TABLE 2 EUROPE IMMUNOTHERAPY MARKET, BY COUNTRY, 2019-2036 (USD MILLION) 16
TABLE 3 EUROPE IMMUNOTHERAPY MARKET , BY MOLECULE/PRODUCT, 2019-2036 (USD MILLION) 17
TABLE 4 EUROPE IMMUNOTHERAPY MARKET , BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MILLION) 17
TABLE 5 EUROPE IMMUNOTHERAPY MARKET , BY BIOLOGICIC IMMUNOTHERAPY, 2019-2036 (USD MILLION) 17
TABLE 6 EUROPE IMMUNOTHERAPY MARKET , BY APPLICATION, 2019-2036 (USD MILLION) 19
TABLE 7 EUROPE IMMUNOTHERAPY MARKET , BY RESPIRATORY ALLERGIES, 2019-2036 (USD MILLION) 19
TABLE 8 EUROPE IMMUNOTHERAPY MARKET , BY ATOPIC DISEASES, 2019-2036 (USD MILLION) 19
TABLE 9 EUROPE IMMUNOTHERAPY MARKET , BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MILLION) 21
TABLE 10 EUROPE IMMUNOTHERAPY MARKET , BY AGE GROUP, 2019-2036 (USD MILLION) 21
TABLE 11 EUROPE IMMUNOTHERAPY MARKET , BY END USER, 2019-2036 (USD MILLION) 21
TABLE 12 GERMANY IMMUNOTHERAPY MARKET , BY MOLECULE/PRODUCT, 2019-2036 (USD MILLION) 23
TABLE 13 GERMANY IMMUNOTHERAPY MARKET , BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MILLION) 23
TABLE 14 GERMANY IMMUNOTHERAPY MARKET , BY BIOLOGICIC IMMUNOTHERAPY, 2019-2036 (USD MILLION) 23
TABLE 15 GERMANY IMMUNOTHERAPY MARKET , BY APPLICATION, 2019-2036 (USD MILLION) 24
TABLE 16 GERMANY IMMUNOTHERAPY MARKET , BY RESPIRATORY ALLERGIES, 2019-2036 (USD MILLION) 24
TABLE 17 GERMANY IMMUNOTHERAPY MARKET , BY ATOPIC DISEASES, 2019-2036 (USD MILLION) 25
TABLE 18 GERMANY IMMUNOTHERAPY MARKET , BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MILLION) 26
TABLE 19 GERMANY IMMUNOTHERAPY MARKET , BY AGE GROUP, 2019-2036 (USD MILLION) 26
TABLE 20 GERMANY IMMUNOTHERAPY MARKET , BY END USER, 2019-2036 (USD MILLION) 26
TABLE 21 UK IMMUNOTHERAPY MARKET , BY MOLECULE/PRODUCT, 2019-2036 (USD MILLION) 28
TABLE 22 UK IMMUNOTHERAPY MARKET , BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MILLION) 28
TABLE 23 UK IMMUNOTHERAPY MARKET , BY BIOLOGICIC IMMUNOTHERAPY, 2019-2036 (USD MILLION) 28
TABLE 24 UK IMMUNOTHERAPY MARKET , BY APPLICATION, 2019-2036 (USD MILLION) 29
TABLE 25 UK IMMUNOTHERAPY MARKET , BY RESPIRATORY ALLERGIES, 2019-2036 (USD MILLION) 29
TABLE 26 UK IMMUNOTHERAPY MARKET , BY ATOPIC DISEASES, 2019-2036 (USD MILLION) 30
TABLE 27 UK IMMUNOTHERAPY MARKET , BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MILLION) 31
TABLE 28 UK IMMUNOTHERAPY MARKET , BY AGE GROUP, 2019-2036 (USD MILLION) 31
TABLE 29 UK IMMUNOTHERAPY MARKET , BY END USER, 2019-2036 (USD MILLION) 31
TABLE 30 FRANCE IMMUNOTHERAPY MARKET , BY MOLECULE/PRODUCT, 2019-2036 (USD MILLION) 33
TABLE 31 FRANCE IMMUNOTHERAPY MARKET , BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MILLION) 33
TABLE 32 FRANCE IMMUNOTHERAPY MARKET , BY BIOLOGICIC IMMUNOTHERAPY, 2019-2036 (USD MILLION) 33
TABLE 33 FRANCE IMMUNOTHERAPY MARKET , BY APPLICATION, 2019-2036 (USD MILLION) 34
TABLE 34 FRANCE IMMUNOTHERAPY MARKET , BY RESPIRATORY ALLERGIES, 2019-2036 (USD MILLION) 34
TABLE 35 FRANCE IMMUNOTHERAPY MARKET , BY ATOPIC DISEASES, 2019-2036 (USD MILLION) 35
TABLE 36 FRANCE IMMUNOTHERAPY MARKET , BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MILLION) 36
TABLE 37 FRANCE IMMUNOTHERAPY MARKET , BY AGE GROUP, 2019-2036 (USD MILLION) 36
TABLE 38 FRANCE IMMUNOTHERAPY MARKET , BY END USER, 2019-2036 (USD MILLION) 36
TABLE 39 ITALY IMMUNOTHERAPY MARKET , BY MOLECULE/PRODUCT, 2019-2036 (USD MILLION) 38
TABLE 40 ITALY IMMUNOTHERAPY MARKET , BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MILLION) 38
TABLE 41 ITALY IMMUNOTHERAPY MARKET , BY BIOLOGICIC IMMUNOTHERAPY, 2019-2036 (USD MILLION) 38
TABLE 42 ITALY IMMUNOTHERAPY MARKET , BY APPLICATION, 2019-2036 (USD MILLION) 39
TABLE 43 ITALY IMMUNOTHERAPY MARKET , BY RESPIRATORY ALLERGIES, 2019-2036 (USD MILLION) 39
TABLE 44 ITALY IMMUNOTHERAPY MARKET , BY ATOPIC DISEASES, 2019-2036 (USD MILLION) 40
TABLE 45 ITALY IMMUNOTHERAPY MARKET , BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MILLION) 41
TABLE 46 ITALY IMMUNOTHERAPY MARKET , BY AGE GROUP, 2019-2036 (USD MILLION) 41
TABLE 47 ITALY IMMUNOTHERAPY MARKET , BY END USER, 2019-2036 (USD MILLION) 41
TABLE 48 SPAIN IMMUNOTHERAPY MARKET , BY MOLECULE/PRODUCT, 2019-2036 (USD MILLION) 43
TABLE 49 SPAIN IMMUNOTHERAPY MARKET , BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MILLION) 43
TABLE 50 SPAIN IMMUNOTHERAPY MARKET , BY BIOLOGICIC IMMUNOTHERAPY, 2019-2036 (USD MILLION) 43
TABLE 51 SPAIN IMMUNOTHERAPY MARKET , BY APPLICATION, 2019-2036 (USD MILLION) 44
TABLE 52 SPAIN IMMUNOTHERAPY MARKET , BY RESPIRATORY ALLERGIES, 2019-2036 (USD MILLION) 44
TABLE 53 SPAIN IMMUNOTHERAPY MARKET , BY ATOPIC DISEASES, 2019-2036 (USD MILLION) 45
TABLE 54 SPAIN IMMUNOTHERAPY MARKET , BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MILLION) 46
TABLE 55 SPAIN IMMUNOTHERAPY MARKET , BY AGE GROUP, 2019-2036 (USD MILLION) 46
TABLE 56 SPAIN IMMUNOTHERAPY MARKET , BY END USER, 2019-2036 (USD MILLION) 46
TABLE 57 BELGIUM IMMUNOTHERAPY MARKET, BY MOLECULE/PRODUCT 2019-2036 (USD MN) 48
TABLE 58 BELGIUM IMMUNOTHERAPY MARKET, BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MN) 48
TABLE 59 BELGIUM IMMUNOTHERAPY MARKET, BY BIOLOGIC IMMUNOTHERAPY, 2019-2036 (USD MN) 48
TABLE 60 BELGIUM IMMUNOTHERAPY MARKET, BY APPLICATION, 2019-2036 (USD MN) 50
TABLE 61 BELGIUM IMMUNOTHERAPY MARKET, BY RESPIRATORY ALLERGIES,2019-2036 (USD MN) 50
TABLE 62 BELGIUM IMMUNOTHERAPY MARKET, BY ATOPIC DISEASES,2019-2036 (USD MN) 50
TABLE 63 BELGIUM IMMUNOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MN) 51
TABLE 64 BELGIUM IMMUNOTHERAPY MARKET, BY AGE GROUP, 2019-2036 (USD MN) 51
TABLE 65 BELGIUM IMMUNOTHERAPY MARKET, BY END USER,2019-2036 (USD MN) 51
TABLE 66 DENMARK IMMUNOTHERAPY MARKET, BY MOLECULE/PRODUCT 2019-2036 (USD MN) 53
TABLE 67 DENMARK IMMUNOTHERAPY MARKET, BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MN) 53
TABLE 68 DENMARK IMMUNOTHERAPY MARKET, BY BIOLOGIC IMMUNOTHERAPY, 2019-2036 (USD MN) 53
TABLE 69 DENMARK IMMUNOTHERAPY MARKET, BY APPLICATION, 2019-2036 (USD MN) 55
TABLE 70 DENMARK IMMUNOTHERAPY MARKET, BY RESPIRATORY ALLERGIES,2019-2036 (USD MN) 55
TABLE 71 DENMARK IMMUNOTHERAPY MARKET, BY ATOPIC DISEASES,2019-2036 (USD MN) 55
TABLE 72 DENMARK IMMUNOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MN) 57
TABLE 73 DENMARK IMMUNOTHERAPY MARKET, BY AGE GROUP, 2019-2036 (USD MN) 57
TABLE 74 DENMARK IMMUNOTHERAPY MARKET, BY END USER,2019-2036 (USD MN) 57
TABLE 75 NETHERLAND IMMUNOTHERAPY MARKET, BY MOLECULE/PRODUCT 2019-2036 (USD MN) 59
TABLE 76 NETHERLAND IMMUNOTHERAPY MARKET, BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MN) 59
TABLE 77 NETHERLAND IMMUNOTHERAPY MARKET, BY BIOLOGIC IMMUNOTHERAPY, 2019-2036 (USD MN) 59
TABLE 78 NETHERLAND IMMUNOTHERAPY MARKET, BY APPLICATION, 2019-2036 (USD MN) 61
TABLE 79 NETHERLAND IMMUNOTHERAPY MARKET, BY RESPIRATORY ALLERGIES,2019-2036 (USD MN) 61
TABLE 80 NETHERLAND IMMUNOTHERAPY MARKET, BY ATOPIC DISEASES,2019-2036 (USD MN) 61
TABLE 81 NETHERLAND IMMUNOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MN) 63
TABLE 82 NETHERLAND IMMUNOTHERAPY MARKET, BY AGE GROUP, 2019-2036 (USD MN) 63
TABLE 83 NETHERLAND IMMUNOTHERAPY MARKET, BY END USER,2019-2036 (USD MN) 63
TABLE 84 SWEDEN IMMUNOTHERAPY MARKET, BY MOLECULE/PRODUCT 2019-2036 (USD MN) 65
TABLE 85 SWEDEN IMMUNOTHERAPY MARKET, BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MN) 65
TABLE 86 SWEDEN IMMUNOTHERAPY MARKET, BY BIOLOGIC IMMUNOTHERAPY, 2019-2036 (USD MN) 65
TABLE 87 SWEDEN IMMUNOTHERAPY MARKET, BY APPLICATION, 2019-2036 (USD MN) 67
TABLE 88 SWEDEN IMMUNOTHERAPY MARKET, BY RESPIRATORY ALLERGIES,2019-2036 (USD MN) 67
TABLE 89 SWEDEN IMMUNOTHERAPY MARKET, BY ATOPIC DISEASES,2019-2036 (USD MN) 67
TABLE 90 SWEDEN IMMUNOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MN) 69
TABLE 91 SWEDEN IMMUNOTHERAPY MARKET, BY AGE GROUP, 2019-2036 (USD MN) 69
TABLE 92 SWEDEN IMMUNOTHERAPY MARKET, BY END USER,2019-2036 (USD MN) 69
TABLE 93 POLAND IMMUNOTHERAPY MARKET, BY MOLECULE/PRODUCT 2019-2036 (USD MN) 71
TABLE 94 POLAND IMMUNOTHERAPY MARKET, BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MN) 71
TABLE 95 POLAND IMMUNOTHERAPY MARKET, BY BIOLOGIC IMMUNOTHERAPY, 2019-2036 (USD MN) 71
TABLE 96 POLAND IMMUNOTHERAPY MARKET, BY APPLICATION, 2019-2036 (USD MN) 73
TABLE 97 POLAND IMMUNOTHERAPY MARKET, BY RESPIRATORY ALLERGIES,2019-2036 (USD MN) 73
TABLE 98 POLAND IMMUNOTHERAPY MARKET, BY ATOPIC DISEASES,2019-2036 (USD MN) 73
TABLE 99 POLAND IMMUNOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MN) 75
TABLE 100 POLAND IMMUNOTHERAPY MARKET, BY AGE GROUP, 2019-2036 (USD MN) 75
TABLE 101 POLAND IMMUNOTHERAPY MARKET, BY END USER,2019-2036 (USD MN) 75
TABLE 102 REST OF EUROPE IMMUNOTHERAPY MARKET, BY MOLECULE/PRODUCT 2019-2036 (USD MN) 77
TABLE 103 REST OF EUROPE IMMUNOTHERAPY MARKET, BY ALLERGEN-SPECIFIC IMMUNOTHERAPY (AIT), 2019-2036 (USD MN) 77
TABLE 104 REST OF EUROPE IMMUNOTHERAPY MARKET, BY BIOLOGIC IMMUNOTHERAPY, 2019-2036 (USD MN) 77
TABLE 105 REST OF EUROPE IMMUNOTHERAPY MARKET, BY APPLICATION, 2019-2036 (USD MN) 79
TABLE 106 REST OF EUROPE IMMUNOTHERAPY MARKET, BY RESPIRATORY ALLERGIES,2019-2036 (USD MN) 79
TABLE 107 REST OF EUROPE IMMUNOTHERAPY MARKET, BY ATOPIC DISEASES,2019-2036 (USD MN) 79
TABLE 108 REST OF EUROPE IMMUNOTHERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2036 (USD MN) 81
TABLE 109 REST OF EUROPE IMMUNOTHERAPY MARKET, BY AGE GROUP, 2019-2036 (USD MN) 81
TABLE 110 REST OF EUROPE IMMUNOTHERAPY MARKET, BY END USER,2019-2036 (USD MN) 81
LIST OF FIGURES
FIGURE 1 NA & EUROPE MARKET ANALYSIS: IMMUNOTHERAPYS MARKET, 2019-2035 (USD MILLION) 11
FIGURE 1 NA & EUROPE IMMUNOTHERAPY MARKET, BY REGION, 2025 (% SHARE) 13
FIGURE 2 EUROPE: SWOT ANALYSIS 14
FIGURE 3 EUROPE IMMUNOTHERAPY MARKET , BY REGION, 2025 & 2036 (USD MILLION) 14
FIGURE 4 EUROPE IMMUNOTHERAPY MARKET SHARE (%), BY COUNTRY, 2025 15
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Market Research Future 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們